Physician profile
David F Chang
NPI 1043266240
$4,665.57
in general payments reported to CMS, 2019-2025
32 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $312 · 2021: $196 · 2022: $862 · 2023: $1,063 · 2024: $842 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,053 · Education: $56.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,053.31 |
| Education | $56.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $825.06 | 2021-2025 | |
| Vifor Pharma, INC. | $680.97 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals Lp | $402.20 | 2021-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $249.48 | 2023-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $229.52 | 2023-2025 | Lupkynis |
| Ardelyx, INC. | $218.21 | 2023-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $209.35 | 2022-2025 | Acthar, Amitiza |
| Glaxosmithkline, LLC. | $192.65 | 2022-2025 | Benlysta, Shingrix |
| Calliditas Therapeutics US INC. | $173.41 | 2022-2025 | Tarpeyo |
| Amgen INC. | $163.27 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Ani Pharmaceuticals, INC. | $160.86 | 2022-2025 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $128.78 | 2019-2025 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $120.42 | 2023-2025 | |
| Boston Scientific Corporation | $106.66 | 2019-2022 | |
| Horizon Therapeutics Plc | $87.31 | 2019-2023 | Krystexxa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $76.24 | 2023-2024 | Velphoro |
| Novo Nordisk INC | $71.11 | 2023-2025 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $65.25 | 2023-2024 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $63.05 | 2025 | Livtencity |
| Otsuka America Pharmaceutical, INC. | $62.91 | 2020-2025 | Voyxact, Jynarque |
| Alexion Pharmaceuticals, INC. | $57.83 | 2023 | Ultomiris |
| Medtronic, INC. | $51.04 | 2025 | Symplicity G3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.97 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $39.33 | 2022-2025 | Zepbound, Mounjaro |
| Cumberland Pharmaceuticals, INC. | $36.53 | 2020 | |
| Kyowa Kirin, INC. | $29.84 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $24.76 | 2024 | |
| Genzyme Corporation | $21.76 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $21.43 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.74 | 2019 | |
| Opko Pharmaceuticals, LLC | $18.48 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.